This Solicitation opportunity from Government of Canada was posted on June 29, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

ACAN Autoinjector atropine and pralidoxime chloride

Closed

WS5677517247International

Submission Closed06/29/2026, 02:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325412

New

DIBBS

Medical Electrode Gel Manufacturing and SupplyThe contract entails the manufacture and delivery of a specialized electrode gel designed for EKG applications, requiring the product to be clear, salt-free, non-staining, and corrosion-resistant to ensure optimal performance and patient safety. The gel must be packaged in 8.5 oz tubes, with twelve tubes per box, and must maintain its integrity and effectiveness over a 48-month shelf life, ensuring long-term usability without degradation. Delivery terms specify FOB Destination to Scott AFB, IL, indicating the vendor assumes responsibility for all shipping costs and risks until the product reaches the designated military location. The solicitation is classified as a subcontract under NAICS code 325412, which corresponds to pharmaceutical and medicine manufacturing, and is issued by the Department of Defense through its Medical Supply Chain division. Responses are due by August 3, 2026, with the opportunity posted on July 26, 2026, suggesting a competitive bidding window of approximately one week to secure the supply agreement.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

Manufacture of Chlorine Test Reagent (DPD Powder Pillows)

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

SODIUM CHLORIDE INJECTSodium Chloride Injection 0.9% in 250 mL units, packaged 24 bags per purchase group, is being procured under solicitation SPE2DP-26-T-4271 with a delivery requirement of five days FOB destination. The item is regulated by the FDA and must comply with strict packaging and marking standards as defined by Medical Marking Standard No. 1, superseding all references to MIL-STD-129. Each unit must be sealed in commercial-grade containers that protect against damage and breakage, and all exterior shipping containers must ensure safe, cost-effective delivery by common carriers. The product has a non-extendable shelf life of 24 months and must be stored at room temperature with brief exposure to up to 40°C permitted without adverse effect. The item is identified by NSN 6505-01-331-8945 and is subject to zero variance in quantity, with inspection and acceptance occurring at the destination. Multiple manufacturers including B. Braun Medical Inc., ICU Medical Inc., Trillamed LLC, and Cardinal Health 200, LLC are qualified suppliers, each identified by specific NDC numbers and part numbers. All packaging and labeling must conform to the latest Medical Marking Standard No. 1, available through DLA Troop Support, and the solicitation includes requirements for covered defense information. The contracting officer must submit a referral in EBS for product confirmation prior to award, including bidder and manufacturer details.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

ACEPROMAZINE MALEATE IACEPROMAZINE MALEATE INJECTION, VETERINARY, 10MG/ML in 50ML vials, is being procured under solicitation SPE2DP-26-T-4274 for use in cats, dogs, and horses, with explicit prohibition against use in horses intended for human consumption. The unit of issue is a vial (VI), and the contract calls for delivery of two vials, with a firm fixed price of $25.03 per vial, resulting in a total estimated contract value of approximately $1,078. Delivery is required within 62 days after award, FOB destination, to a designated military medical logistics center in Kaiserslautern, Germany. The product must be stored at controlled room temperature, between 20–25°C (68–77°F), and carries a non-extendable shelf life of 36 months as a TYPE I (CODE Q) item. Packaging must strictly adhere to MIL-STD-2073-1E, and all marking must comply with the latest Medical Marking Standard No. 1, superseding MIL-STD-129. As a hazardous material, the product requires GHS-compliant labeling under OSHA’s Hazard Communication Standard (29 CFR 1910.1200), with Safety Data Sheets submitted and approved prior to award. The supplier must also train personnel on SDS and labeling requirements and ensure all packaging and labeling meet the updated Federal Standard No. 313-E. Transportation of the shipment by sea must be conducted using U.S.-flag vessels unless a waiver is granted with prior documentation. The contract includes mandatory compliance with numerous DFARS clauses, including those addressing disclosure of information, whistleblower rights, restrictions on former DoD officials’ compensation, control of government work product, and NIST SP 800-171 cybersecurity requirements. The contractor must provide a Unique Entity Identifier and CAGE code, represent its small business status if applicable, and certify compliance with socioeconomic program requirements. Inspection and acceptance occur at destination, with full responsibility for quality, packaging, and regulatory compliance resting with the supplier. All proposals must be submitted electronically via the DLA Internet Bid Board System by the August 3, 2026 deadline, following DLA’s Master Solicitation for Automated Simplified Acquisitions.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

POVIDONE-IODINE TOPICAPOVIDONE-IODINE TOPICAL SOLUTION, USP, is a regulated pharmaceutical product procured under contract SPE2DP-26-T-4280 for U.S. military use, with each unit being a 4 fluid ounce (118 mL) bottle identified by the unit of issue BT and NSN 6505010672812. The product must comply with stringent technical and quality requirements from the DLA Master List, including a mandatory 36-month shelf life, of which at least 31 months must remain at time of delivery to the first government activity. Labeling must conform to MED.MARKING STD 1A, specifying key elements such as manufacturer and CAGE code, manufacturing and expiration dates, contract and lot numbers, and the unit designation 1 BT = 4 OZ. The product is subject to FDA regulation and requires pre-award referral through EBS for validation. Packaging must be commercial-grade, sealed to prevent damage, and shipped in exterior containers ensuring safe transit at minimal cost, adhering to DLA’s packaging directives over ASTM D3951 when applicable, with all marking strictly following MIL-STD-129 despite references to MMS No. 1. The material is classified as non-hazardous per FED-STD-313 and must be shipped by traceable means only, prohibiting parcel post. Two delivery points are specified: Fort Bragg, NC and Fort Bliss, TX, each requiring shipment within 20 days of contract award with no tolerance for quantity variance. Delivery is FOB destination, with inspection and acceptance occurring at the final location. The solicitation lists Cardinal Health 200, LLC and Purdue Pharma LP as potential manufacturers under NDC 67618-0150-04, and procurement is coordinated through DLA Troop Support, with point of contact Shairy M. Cartagena.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

ZINC OXIDE OINTMENTZinc Oxide Ointment USP, containing 20% zinc oxide in a 28.35 gram collapsible tube, is a topical skin protectant procured under solicitation SPE2DP-26-T-4279 with a requirement for five units of issue. The product must comply with the latest Medical Marking Standard No. 1, be labeled with NDC 67777-0223-11, and be manufactured by Dynarex Corp under part number 1TVZ3. It is subject to a non-extendable shelf life of 36 months as a TYPE I Q-coded item and must be stored at controlled room temperature not exceeding 30°C. Packaging must adhere to DLA Packaging Requirements for Procurement, MIL-STD-129, and ASTM D3951 if non-hazardous, with all markings and labeling controlled by the DLA Master List of Technical and Quality Requirements. The item is regulated by the FDA, requiring referral through EBS for confirmation, and is subject to Covered Defense Information protocols. Delivery is FOB destination within 20 days of contract award, with no variance allowed in quantity, inspection and acceptance occurring at the destination point. The sole delivery address is W51JYU, 0165 CS HHC HHC Combat Sustainment, Bossier City, LA 71111-5397, and shipment must be sent via traceable means, excluding parcel post. The contract specifies a unit price of $5.00 per tube, totaling $25.00, with the original required delivery date set for July 28, 2026. All technical and quality obligations referenced by R-numbers are governed by the DLA Master List in effect on the solicitation issue date, and the product must be palletized in accordance with RP001. Government use only identifiers and tracking codes, including the TCN and SUPP ADD, are included for logistics and accountability purposes, with the contracting office listed as the Department of Defense, Medical Supply Chain PHARM FSA.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

VECURONIUM BROMIDE FORVecuronium Bromide for Injection is a freeze-dried powder containing 10 mg of the active ingredient, supplied in packages of ten vials per unit, with a total shelf life of 24 months. At the time of receipt by the first government activity, the product must have a minimum of 21 months of remaining shelf life, and storage must be maintained at controlled room temperature between 20 to 25°C (68 to 77°F), protected from light and retained in its original carton until use. The item is classified as a Type I (Code M) medical supply with a non-extendable shelf life, and all packaging and marking must comply with Medical Marking Standard No. 1, which supersedes MIL-STD-129. Each unit must be sealed in a protective container and packed in commercial shipping containers ensuring safe delivery at the lowest cost to the specified destination, with strict adherence to hazardous materials shipping protocols. The product, manufactured by Hikma Pharmaceuticals USA Inc., is identified by NDC 00143-9234-10 and NSN 6505-01-258-0983, and is required for delivery to JBER, Alaska, under contract SPE2DP-26-T-4283 with a firm delivery date of July 28, 2026. The procurement specifies a fixed quantity of three units totaling two packages, with no variance permitted, and all shipments must be routed through designated government freight and parcel post addresses. Compliance with DLA packaging, technical, and quality requirements, as outlined in the DLA Master List and supporting directives, is mandatory.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

TOLNAFTATE POWDER, UThe contract specifies the procurement of Tolnaftate Powder, USP 1%, in 45-gram units, with a total quantity of two BT units, each equivalent to 45 grams, under solicitation SPE2DP-26-T-4282. The item is designated as a Type I (Code Q) medical product with a strict non-extendable shelf life of 36 months, and packaging must comply with commercial standards as outlined in the procurement document, ensuring protection against damage and secure transit via common carrier at the lowest cost to the delivery point. All packaging and labeling must adhere to Medical Marking Standard No. 1, which supersedes MIL-STD-129, and includes proper identification and marking requirements for defense-related materials. Delivery is required FOB destination within five days, with no variance permitted in quantity, and inspection and acceptance occur at the destination. The item is sourced from Geri-Care Pharmaceuticals Corp. under NDC57896-0199-45, and the contract mandates compliance with DLA’s Technical and Quality Requirements as defined in the DLA Master List, with applicable provisions for Covered Defense Information. The place of performance is Mountain Home AFB, ID, and the contracting office is the Department of Defense’s Medical Supply Chain Pharm FSA, with point of contact Imerah Burnett.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

RINGER'S INJECTION, LACRINGER'S INJECTION, LACTATED, USP, 1000ML, in packs of 12 units per case, is subject to strict packaging and marking requirements mandated by the Department of Defense. Each unit must be sealed in a protective container to prevent damage or breakage, and all shipments must be packed in commercial exterior containers suitable for safe transport via common carrier at the lowest cost to the designated delivery point. Packaging must comply with Medical Marking Standard No. 1, which supersedes MIL-STD-129, and all markings must adhere to the latest edition of this standard as published by DLA Troop Support. The product is regulated by the FDA and requires confirmation by a product specialist prior to award, with bidder and manufacturer details submitted through EBS. The item has a non-extendable shelf life of 30 months and must be stored at room temperature (25°C), with brief exposure to up to 40°C permitted without adverse effects. It is prohibited from freezing and must be protected from excessive heat. The contract specifies a quantity of 2 packaging groups, each containing 12 units, for delivery to Dyess AFB within 20 days under FOB destination terms with zero variance allowed. Inspection and acceptance occur at the delivery point, and the item is identified by NSN 6505-01-330-6267 and manufacturer part number NDC00264-7750-00 under B. BRAUN MEDICAL INC. The solicitation, issued under contract SPE2DP-26-T-4292, has an August 3, 2026 response deadline and falls under NAICS code 325412 for pharmaceutical manufacturing.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

TEST STRIPS AND COLORThe contract specifies the procurement of test strips and color charts for urine analysis, detecting bilirubin, blood, glucose, ketone, leukocytes, nitrite, pH, protein, specific gravity, and urobilinogen. Each unit of issue is a bottle containing 100 strips, and the item is identified by NSN 6550-01-221-5400 with a purchase quantity of four bottles. The product must comply with stringent technical and quality requirements referenced in the DLA Master List, and packaging must adhere to commercial standards as well as the Medical Marking Standard No. 1, which supersedes MIL-STD-129. Each unit must be sealed in a protective container, and shipping containers must ensure safe, cost-effective delivery to the specified FPO address. The item is classified as a Type I (Code K) with a non-extendable shelf life of 18 months, and no more than two months may have elapsed between the date of manufacture and the delivery date to the government. All labels must clearly indicate the date of manufacture, expiration or retest date, and the contract or lot number, in accordance with the latest MMS1C guidelines. The solicitation was issued under SPE2DS-26-T-269W with a response deadline of August 3, 2026, and delivery is required within 20 days after award.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

DEXTROSE, POTASSIUM CHLThe contract specifies the procurement of 1000 mL sterile injection solution containing 5 percent dextrose, 0.15 percent potassium chloride, and 0.45 percent sodium chloride, manufactured by Baxter Healthcare Corporation under NDC 00338-0671-04 and part number 2B1654X, packaged in units of 14 per pack (PG), with a total quantity of one unit. The item is regulated by the FDA and subject to strict packaging, marking, and shelf-life requirements; it must have a non-extendable 24-month shelf life and be commercially packaged to protect against damage during transit. All packaging and labeling must comply with Medical Marking Standard No. 1, superseding MIL-STD-129, and must adhere to DLA’s Master List of Technical and Quality Requirements, which take precedence over other standards such as ASTM D3951. Hazardous material handling protocols under FED-STD-313 and TQ requirement IP025 apply if applicable. The item must be palletized in accordance with DLA packaging requirements, shipped via the fastest traceable means excluding parcel post, and delivered FOB destination to Fort Stewart, Georgia within 20 days of contract award. The required delivery date is July 24, 2026, with zero variance allowed in quantity. The solicitation number is SPE2DP-26-T-4278, with a response deadline of August 3, 2026, and the North American Industry Classification System code is 325412. Government use designation and shipping instructions include specific codes and identifiers for logistics and tracking purposes.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

CHLORINE TEST REAGEThe contract specifies the procurement of Chlorine Test Reagent, a DPD total chlorine reagent supplied in 100 powder pillows, each designed for a 10 mL sample size, with the unit of issue being one package containing 100 pillows. The item is identified by NSN 6550-01-460-7597 and must meet stringent technical and quality requirements referenced from the DLA Master List of Technical and Quality Requirements. It is subject to DLA packaging standards, including commercial packaging for all medical acquisitions, requiring each unit to be sealed in a protective container and shipped in suitable exterior packaging to ensure safe delivery at the lowest carrier rate. All markings must comply with Medical Marking Standard No. 1, which supersedes MIL-STD-129, and must include the date of manufacture, expiration or retest date, and the contract or lot number in accordance with the latest revision of MMS1C. The item is classified as a TYPE I (CODE S) with a mandatory 60-month shelf life that is non-extendable, and no more than eight months may have passed between the date of manufacture and the date of delivery to the government. The solicitation, issued under SPE2DS-26-T-269Y on July 26, 2026, requires delivery within 20 days after order and is managed by the Department of Defense’s Medical Supply Chain, with Seth Tootell as the primary point of contact.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

1 day ago

DEADLINE

in 7 days

AI Contract Overview

Public Services and Procurement Canada is issuing an Advanced Contract Award Notice for the procurement of dual-chamber autoinjectors containing atropine and pralidoxime chloride under solicitation number WS5677517247. This notice, posted on June 29, 2026, is intended to inform the supplier community of the government's intent to award a contract to a pre-identified supplier unless another supplier submits a qualifying statement of capabilities by the deadline of June 29, 2026 at 14:00 EST. The requirement falls under NAICS code 325412 and is being managed by the Government of Canada through the Department of Public Works and Government Services. Suppliers are invited to respond with their capabilities in accordance with the terms outlined in the advanced notice, with delivery expected to occur in the United Kingdom of Great Britain and Northern Ireland and Canada. The primary point of contact for inquiries is Anja Ramenason of SPAC/PSPC, reachable via email at anja.ramenason@tpsgc-pwgsc.gc.ca. The notice can be accessed through the specified public portal link.

General Info

Government seeks dual-chamber autoinjectors; responses due June 29, 2026 for Canada and UK delivery.

Agency

Government of Canada → Department of Public Works and Government ServicesView Agency

NAICS

325412 - Pharmaceutical Preparation ManufacturingView NAICS

Place of Performance

*United Kingdom of Great Britain and Northern Ireland *Canada, CAN

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PhaseClosed

PostedJun 11

Solicitation

Response DeadlineJun 29

Deadline has passed

Submission Closed

06/29/2026, 02:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyGovernment of Canada → Department of Public Works and Government Services

Contacts1 person available

OfficeN/A

Organization / Agency

Government of Canada → Department of Public Works and Government Services

View Agency Profile

Office AddressN/A

Contacts

Ramenason Anja (SPAC/PSPCPoint of Contact

contact@example.gov

Full Description

An Advanced Contract Award Notice (ACAN) is a public notice indicating to the supplier community that a department or agency intends to award a contract for goods, services or construction to a pre-identified supplier, thereby allowing other suppliers to signal their interest in bidding, by submitting a statement of capabilities. If no supplier submits a statement of capabilities that meets the requirements set out in the ACAN, on or before the closing date stated in the ACAN, the contracting officer may then proceed with the award to the pre identified supplier. Public Services and Procurement Canada is issuing this ACAN notice for the acquisition of dual-chamber autoinjectors containing atropine and pralidoxime chloride. All details related to the requirement are found in the advanced notice.